May 6th 2025
The goal of the proposed bill is to “make prescriptions affordable again” in the US.
Managing Disparities in Chronic Kidney Disease Through Value-Based Arrangements
November 9th 2021On this episode of Managed Care Cast, we speak with Abi Sundaramoorthy, MD, MBA, executive vice president of clinical enterprise at Somatus, on fragmented care in chronic kidney disease, its disproportionate impact on minority communities, and the potential of value-based arrangements to address disparities and promote preventive, effective care.
Listen
For Optimal Cost-effectiveness, Strategize Biologic Therapy for Severe Asthma
November 8th 2021To avoid bankrupting health care, providers must carefully consider how they use biologics in patients with severe asthma, according to a presenter at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
Read More
AMCP Nexus Abstracts Present Findings on Clinical, Financial Burdens Associated With CKD
November 8th 2021Conference abstracts explored the relationship between serum phosphate levels on mortality in patients with chronic kidney disease (CKD) and cost burdens for employers as patients transition to end-stage renal disease.
Read More
In AD Biologics Debate, Therapy Choice Is Just Half of the Battle
November 5th 2021With new and expected future options for treating atopic dermatitis (AD), including an injectable biologic and an oral small molecule inhibitor, which is preferred and which makes the most sense for patients?
Read More
Aligning Value and Cost Considerations to Improve Access to, Outcomes of Gene Therapies
October 29th 2021A panel at Asembia 2021 Specialty Pharmacy Summit in Las Vegas addressed challenges in the treatment journey of patients with rare diseases, efforts to improve access to gene therapies, and cost and value considerations for stakeholders.
Read More
Dr Michelle Booth Discusses Exciting Developments in the Oncology Pipeline
October 28th 2021Oncology drugs are a huge driver of cost, but there’s a lot of innovation happening in the space to improve care and outcomes for patients, said Michelle Booth, PharmD, director of specialty clinical solutions at Magellan Rx Management.
Watch
The state of value-based contracting in specialty pharmacy was addressed in a panel discussion at Asembia 2021 Specialty Pharmacy Summit in Las Vegas, with speakers touching on the essentials of such agreements, how to optimally integrate them, and future considerations for the pharmaceutical marketplace.
Read More
Investigating if 340B Led to Improved Care in Underserved Populations
October 28th 2021In the years since its inception, debates around the 340B program have centered on whether savings actually benefit the underserved as intended. A new paper in The American Journal of Managed Care® analyzed secondary data on 340B participation and uncompensated care provision from general acute care and critical access hospitals between 2003 and 2015.
Listen
Unraveling the Growing Influence of Consolidation, 340B, and Industry in Specialty Pharmacy
October 27th 2021Panelists of the opening session at Asembia 2021 Specialty Pharmacy Summit in Las Vegas address emerging shifts in specialty pharmacy, its impact on the health care system, and future implications post pandemic.
Read More
Comparing Costs and HRU for Tisagenlecleucel vs Axicabtagene Ciloleucel for DLBCL
October 25th 2021Posters presented at AMCP Nexus 2021 evaluated the health care resource utilization (HRU) and costs associated with the chimeric antigen receptor T-cell therapies tisagenlecleucel and axicabtagene ciloleucel.
Read More
Dr Jane Barlow: Novel Financing Can Improve Access, Remove Barriers to Novel Therapies
October 20th 2021Novel financial concepts will help to ensure sustainable access to gene and cell therapies, which may help reduce disparities, said Jane F. Barlow, MD, MPH, MBA, senior advisor, FoCUS Project, MIT Center for Biomedical Innovation, and executive vice president and chief clinical officer at Real Endpoints.
Watch
Adalimumab Biosimilar Shows Equivalent Efficacy, Safety to Reference Humira for Psoriasis
October 20th 2021Adalimumab biosimilar AVT02 exhibited comparative efficacy, safety, tolerability, and immunogenicity to the reference drug Humira in patients with moderate-to-severe chronic plaque psoriasis.
Read More
Study Finds Significant Price Transparency Concerns for Ophthalmologic Procedures
October 11th 2021An evaluation of price transparency tools for ophthalmologic procedures found significant usability, availability, and variability issues, which may disproportionately impact vulnerable populations.
Read More
Ruxolitinib Has Cost-effectiveness, Survival Benefits for Myelofibrosis vs Competitors
October 6th 2021Research presented at EHA2021 shows that the JAK 1/2 inhibitor ruxolitinib produced cost-effective benefits per quality-adjusted life-year and increased the overall survival rate for patients with myelofibrosis.
Read More